Literature DB >> 4053028

Effects of uridine and thymidine on the degradation of 5-fluorouracil, uracil, and thymine by rat liver dihydropyrimidine dehydrogenase.

M Tuchman, M L Ramnaraine, R F O'Dea.   

Abstract

The kinetic properties and control mechanisms of 5-fluorouracil (5-FU), uracil, and thymine degradation by rat liver dihydropyrimidine dehydrogenase were studied in vitro. The calculated Michaelis constant (Km) for 5-FU was 3.49 +/- 0.41 (SE) microM, similar to those for uracil (2.26 +/- 0.28 microM) and for thymine (2.23 +/- 0.34 microM). However, the reduction of 5-FU appears to be most sensitive to the inhibitory effects of increased substrate concentration. The specific activities of dihydropyrimidine dehydrogenase (nmol/min/mg of protein) for 5-FU, uracil, and thymine were 0.82, 0.68, and 0.56, respectively. Uridine was found to be a potent noncompetitive inhibitor of pyrimidine base degradation in vitro, displaying an inhibition constant (Ki) for 5-FU of 0.71 microM. Total inhibition of 5-FU degradation occurred at a uridine concentration of 10 microM, whereas thymidine was found to be a much less potent noncompetitive inhibitor of pyrimidine base degradation (Ki 24 microM). This paper provides the first documentation of in vitro inhibition of dihydropyrimidine dehydrogenase activity by nucleosides. The concomitant utilization of uridine and 5-FU in clinical situations might prove useful by decreasing 5-FU catabolism to toxic metabolites as well as enhancing 5-FU cytotoxicity.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 4053028

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  9 in total

1.  Pyrimidine base degradation in cultured murine C-1300 neuroblastoma cells and in situ tumors.

Authors:  M Tuchman; R F O'Dea; M L Ramnaraine; B L Mirkin
Journal:  J Clin Invest       Date:  1988-02       Impact factor: 14.808

2.  Inhibition of fluorouracil catabolism in cancer patients by the antiviral agent (E)-5-(2-bromovinyl)-2'-deoxyuridine.

Authors:  H J Keizer; E A De Bruijn; U R Tjaden; E De Clercq
Journal:  J Cancer Res Clin Oncol       Date:  1994       Impact factor: 4.553

3.  Phenotypic profiling of DPYD variations relevant to 5-fluorouracil sensitivity using real-time cellular analysis and in vitro measurement of enzyme activity.

Authors:  Steven M Offer; Natalie J Wegner; Croix Fossum; Kangsheng Wang; Robert B Diasio
Journal:  Cancer Res       Date:  2013-01-17       Impact factor: 12.701

4.  Dihydropyrimidine dehydrogenase in normal and malignant endometrium: relationship with cell proliferation and thymidine phosphorylase.

Authors:  Ritsuto Fujiwaki; Kohji Iida; Kentaro Nakayama; Haruhiko Kanasaki; Tomoya Ozaki; Kohkichi Hata; Eiichi Sakai; Kohji Miyazaki
Journal:  Virchows Arch       Date:  2003-08-09       Impact factor: 4.064

5.  Inhibition of intestinal pyrimidine nucleoside phosphorylases.

Authors:  M G Wientjes; J L Au
Journal:  Pharm Res       Date:  1987-10       Impact factor: 4.200

6.  Measurement of in vitro cellular pharmacokinetics of 5-fluorouracil in human and rat cancer cell lines and rat hepatocytes using a flow-through system.

Authors:  E C Spoelstra; H M Pinedo; H Dekker; G J Peters; J Lankelma
Journal:  Cancer Chemother Pharmacol       Date:  1991       Impact factor: 3.333

7.  Modulation of the effects of fluoropyrimidines on toxicity and tumor inhibition in rodents by uridine and thymidine.

Authors:  H R Hartmann; W Bollag
Journal:  Med Oncol Tumor Pharmacother       Date:  1986

8.  Experiment research of focused ultrasound combined with drug and microbubble for treatment of central nervous system leukemia.

Authors:  Xiao-Ping Xi; Yu-Jin Zong; Yan-Hong Ji; Bing Wang; Hua-Sheng Liu
Journal:  Oncotarget       Date:  2017-12-20

9.  Effect of dihydropyrimidine dehydrogenase single nucleotide polymorphisms on prognosis of breast cancer patients with chemotherapy.

Authors:  Fengxia Qin; Huikun Zhang; Yong Huang; Limin Yang; Feng Yu; Xiaoli Liu; Li Fu; Feng Gu; Yongjie Ma
Journal:  Oncotarget       Date:  2017-12-08
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.